The details:
1. Pediatric boosters: Pfizer-BioNTech on April 14 said a booster dose of their COVID-19 vaccine increased the level of neutralizing antibodies against both the original coronavirus strain and the omicron variant among children aged 5 to 11. The findings have not yet been peer reviewed and are based on a Pfizer-led trial of 140 participants.
One month after receiving the booster, children showed a sixfold increase in neutralizing antibody levels against the original coronavirus strain, compared to one month after their second dose. A subanalysis of 30 children indicated a 36-fold increase in antibody levels against omicron after a booster dose. The drugmakers now plan to submit an emergency use authorization request to the FDA for a booster dose in children ages 5-11 “in the coming days.”
2. Vaccination and reinfection: The CDC on April 12 released findings indicating Pfizer and Moderna’s mRNA COVID-19 vaccines strengthen protection against hospitalization among those previously infected. Researchers used EHR data on thousands of patients to conduct the study. They found vaccine effectiveness against COVID-19-related hospitalization among those previously infected during the omicron-predominant period was about 35 percent after two doses, and 68 percent after a booster dose.
“To prevent COVID-19-associated hospitalization, all eligible persons should stay up to date with vaccination, including those with previous SARS-CoV-2 infection,” the report stated.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
